Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group

Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group

Show other versions (1)

<h4>Background</h4> The WHO recommended 1200mg/day of fluconazole (FCZ) in the induction phase of cryptococcal meningitis (CM) in HIV prior to 2018 in regions where amphotericin-B (AMB) was unavailable. A 2-stage AMB-controlled, dose-escalation study to determine the maximum tolerated do...

Full description

Bibliographic Details
Main Authors: Umesh G. Lalloo, Lauren Komarow, Judith A. Aberg, David B. Clifford, Evelyn Hogg, Ashley McKhann, Aggrey Bukuru, David Lagat, Sandy Pillay, Vidya Mave, Khuanchai Supparatpinyo, Wadzanai Samaneka, Deborah Langat, Eduardo Ticona, Sharlaa Badal-Faesen, Robert A. Larsen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925064/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925064/?tool=EBI

Similar Items